SEARCH

SEARCH BY CITATION

References

  • 1
    Hellerstedt BA, Pienta KJ. The current state of hormonal therapy for prostate cancer. CA Cancer J Clin 2002; 52: 154179
  • 2
    Tannock F, de Wit R, Berry WR et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 2004; 351: 15021512
  • 3
    de Bono JS, Oudard S, Ozguroglu M et al. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet 2010; 376: 11471154
  • 4
    de Bono JS, Logothetis CJ, Molina A et al. Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med 2011; 364: 19952005
  • 5
    Scher HI, Fizazi K, Saad F et al. Effect of MDV3100, an androgen receptor signaling inhibitor (ARSI), on overall survival in patients with prostate cancer postdocetaxel: results from the phase III AFFIRM study. J Clin Oncol 2012; 30 (Suppl. 5); abstr LBA1
  • 6
    Parker C, Heinrich D, O'Sullivan JM et al. Overall survival benefit of radium-223 chloride (Alpharadan) in the treatment of patients with symptomatic bone metastasis in castration-resistant prostate cancer: a phase III randomised trial (ALSYMPCA). European Multidisciplinary Cancer Congress (ECCO-ESMO) 2011; Abstract 1LBA
  • 7
    Gontarewicz A, Brümmendorf TH. Danusertib (formerly PHA-739358) – a novel combined pan-aurora kinases and third generation Bcr-Abl tyrosine kinase inhibitor. Recent Results Cancer Res 2010; 184: 199214
  • 8
    Lee ECY, Anna Frolov A, Li R, Ayala G, Greenberg NM. Targeting aurora kinases for the treatment of prostate cancer. Cancer Res 2006; 66: 49965002
  • 9
    Carpinelli P, Ceruti R, Giorgini ML et al. PHA-739358, a potent inhibitor of aurora kinases with a selective target inhibition profile relevant to cancer. Mol Cancer Ther 2007; 6: 31583168
  • 10
    de Ponti R, Colombo A, Moll J et al. PHA-739358 Investigator Brochure. Nerviano Medical Sciences document AURA-6202-IB-2. 26 September 2006
  • 11
    Greenberg NM, DeMayo F, Finegold MJ et al. Prostate cancer in a transgenic mouse. Proc Natl Acad Sci USA 1995; 92: 34393443
  • 12
    Steeghs N, Eskens FA, Gelderblom H et al. Phase I pharmacokinetic and pharmacodynamic study of the aurora kinase inhibitor danusertib in patients with advanced or metastatic solid tumors. J Clin Oncol 2009; 27: 50946001
  • 13
    Cohen RB, Jones SF, Aggarwal C et al. A phase I dose-escalation study of danusertib (PHA-739358) administered as a 24-hour infusion with and without granulocyte colony-stimulating factor in a 14-day cycle in patients with advanced solid tumors. Clin Cancer Res 2009; 15: 66947001
  • 14
    Therasse P, Arbuck SG, Eisenhauer EA et al. New guidelines to evaluate the response to treatment in solid tumors: European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000; 92: 205216
  • 15
    Bubley GJ, Carducci M, Dahut W et al. Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: recommendations from the Prostate-Specific Antigen Working Group. J Clin Oncol 1999; 17: 34613467
  • 16
    Scher HI, Halabi S, Tannock IF et al. Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group. J Clin Oncol 2008; 26: 11481159
  • 17
    National Comprehensive Cancer Network. Clinical Practice Guidelines in Oncology. Adult Cancer Pain. V.1. 2006
  • 18
    Simon R. Optimal two-stage designs for phase II clinical trials. Control Clin Trials 1989; 10: 110
  • 19
    Chieffi P, Cozzolino L, Kisslinger A et al. Aurora B expression directly correlates with prostate cancer malignancy and influence prostate cell proliferation. Prostate 2006; 15: 326333
  • 20
    Beltran H, Rickman DS, Park K et al. Molecular characterization of neuroendocrine prostate cancer and identification of new drug targets. Cancer Discov 2011; 1: 487495
  • 21
    Aparicio A, Logothetis CJ, Maity SN. Understanding the lethal variant of prostate cancer: power of examining extremes. Cancer Discov 2011; 1: 466468
  • 22
    Tagawa ST, Akhtar NH, Robinson BR, Beltran H. Uncommon cancers of the prostate. In Raghavan D et al. ed, Textbook of Uncommon Cancers, 4th edn. Chichester: Wiley, 2012: Chapter 9; Section 1
  • 23
    Beltran H, Tagawa ST, Park K et al. Challenges in recognizing treatment related neuroendocrine prostate cancer. J Clin Oncol 2012 (in press)
  • 24
    Petrylak DP, Ankerst DP, Jiang CS et al. Evaluation of prostate-specific antigen declines for surrogacy in patients treated on SWOG 99-16. J Natl Cancer Inst 2006; 98: 516521
  • 25
    Dawson NA. Response criteria in prostatic carcinoma. Semin Oncol 1999; 26: 174184
  • 26
    Chi KN, Ellard SL, Hotte SJ et al. A phase II study of sorafenib in patients with chemo-naive castration-resistant prostate cancer. Ann Oncol 2008; 19: 746751
  • 27
    Dahut WL, Scripture C, Posadas E et al. A phase II clinical trial of sorafenib in androgen-independent prostate cancer. Clin Cancer Res 2008; 14: 209214